Squamous cell lung cancers, a form of NSCLC, are glucose-dependent, while adenocarcinoma NSCLC tumors are largely glucose-independent.
Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.
Rituximab's mechanism of action may reduce immune surveillance, allowing for the proliferation of cancer cells and infectious agents.
FOLFOXIRI-Bev yields "rapid and deep cytoreduction" that can improve patients' opportunities for metastatic colorectal tumor resection.
Among patients suffering post-radiation or chemoradiation locoregional HNSCC recurrence, those with HPV-positive disease may have better survival rates.
Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.
Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.
Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.
The FDA has granted accelerated approval for the agency's first tissue/site agnostic indication to pembrolizumab.
CMS is working to determine if an episode-based payment model will work in oncology by using information from the 190 practices and 16 commercial payers who are currently participating in OCM.
In this study, researchers developed a strategy to monitor adherence and AEs in real-time using bidirectional texting via BETA-Text.
Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.
The prognostic marker, which was evaluated among patients with stage III NSCLC, held after adjusting for variables including chemoradiation approach and performance status.
A liquid biopsy analysis shows inter- and intra-patient heterogeneity of EGFR resistance mutations among patients with lung adenocarcinoma who received EGFR-directed TKI therapy.
Multiple lines of TKI therapy are associated with higher NRM rates among patients with chronic myelogenous leukemia who undergo allo-HSCT.
Availability of important services and adequacy of care are among the factors explaining low numbers of patients with hematologic cancers being referred for hospice care.
Data suggest that cediranib-treatment of ASPS results in a substantial reduction in tumor burden and prolonged PFS.
SARC024 study met its primary endpoint for patients with Ewing sarcoma, and enrollment is ongoing for the liposarcoma and osteosarcoma cohorts.
Pazopanib showed antitumor efficacy among patients with unresectable or metastatic malignant/dedifferentiated soft fibrous tumors.
KIR3DL1 and HLA-B subtypes mediate NK cell activity against acute myelogenous leukemia and are associated with relapse and mortality after allogeneic hematopoietic cell transplantation.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Cancer Risk Higher in Men Previously Treated for Lymphoma According to Research
- Young Patients With CLL At Risk for Secondary Cancers
- Prostate Cancer Treatment: Abiraterone and Other Hormonal Therapies Being Studied
- Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer
- Green Tea and Cancer